Shortening infusion times for infliximab administration

Shortening infusion times for infliximab administration.

Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.

BACKGROUND AND AIMS Biological therapy with anti TNF agents requires parenteral administration and in the case of infliximab this involves in hospital treatment. We aimed to prospectively assess the safety and tolerance of infliximab infusion in patients with IBD in a specialized unit adhering to strict standard operation procedures including switch to accelerated 1h infusions. METHODS A pros...

Infliximab-Related Infusion Reactions: Systematic Review

OBJECTIVE Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusio...

Severe hidradenitis suppurativa treated with infliximab infusion.

A 17-year-old male patient with a 3-year history of hidradenitis suppurativa presented to our dermatology clinic for more effective treatment. Areas of involvement included the medial aspect of the thighs, scrotum, buttocks, and inframammary folds. His axillae were spared. He also had a pilonidal cyst and nodulocystic acne. A diagnosis of hidradenitis suppurativa was rendered. The patient’s sym...

Linear IgA dermatosis after infliximab infusion for ulcerative colitis

IBD: inflammatory bowel disease LAD: linear IgA dermatosis TNF: tumor necrosis factor UC: ulcerative colitis INTRODUCTION Linear IgA dermatosis (LAD) is an idiopathic or drug-induced autoimmune subepidermal blistering disease characterized by linear deposition of IgA antibodies along the dermoepidermal junction. The pathogenesis, although incompletely understood, involves the formation of derma...